{"source_content":"-1-敬请参阅最后一页特别声明市场价格（人民币）：490.08元市场数据(人民币)总股本(亿股)1.20已上市流通A股(亿股).26总市值(亿元)589.08年内股价最高最低(元)490.08/330.24沪深300指数4699创业板指2651相关报告1.《医美玻尿酸产品龙头，研发+销售驱动高增长-爱美客公司深度研究》，2020.10.10杨芳联系人yangfang1＠gjzq.com.cn袁维分析师SAC执业编号：S1130518080002(8621)60230221yuan_wei＠gjzq.com.cnQ3业绩加速增长，医美玻尿酸行业景气度高公司基本情况(人民币)项目201820192020E2021E2022E营业收入(百万元)3215587081,1111,674营业收入增长率44.28%73.74%26.98%56.88%50.65%归母净利润(百万元)123306401597868归母净利润增长率49.47%148.68%31.10%49.16%45.21%摊薄每股收益(元)1.3653.3953.3324.9717.218每股经营性现金流净额1.483.443.445.337.73ROE(归属母公司)(摊薄)30.84%46.37%9.24%12.73%16.64%P/EN/AN/A147.0798.6067.90P/BN/AN/A13.5912.5511.30来源：公司年报、国金证券研究所业绩简评2020Q1-Q3公司实现营收4.64亿元，同比增长17.4%；归母净利润2.90亿元，同比增长31.8%；扣非后归母净利润2.80亿元，同比增长29.9%。2020Q3公司实现营收2.23亿元，同比增长43.2%；归母净利润1.43亿元，同比增长56.0%；扣非后归母净利润1.39亿元，同比增长55.7%。Q3业绩超预期。经营分析公司各项财务指标整体保持稳定，销售费用率和管理费用率有所下行。Q3毛利率93.0%（去年同期93.3%）维持较高水平；因疫情线下营销活动减少，故销售费用率8.3%（去年同期10.6%）有所下滑；管理费用率5.1%（去年同期7.7%），研发费用率5.5%（去年同期6.7%）。应收账款0.29亿元（年初0.15亿元），主要系销售额增加所致。Q3经营性活动现金净流量1.43亿元（+48.5%），与归母净利润金额持平，现金流维持健康水平。嗨体产品市场定位精准，终端消费需求处于快速增长期，是公司业绩增长的核心驱动。嗨体填补了颈纹修复领域的空白，经过近2年的市场培育，目前安全性和有效性得到越来越多机构的认可，市场需求旺盛。今年6月，公司推出嗨体升级产品嗨体熊猫针，主要用于淡化黑眼圈，市场反响良好。公司是国产玻尿酸终端产品领域的龙头，已形成“5+1”差异化的产品布局，未来有望打造成注射类全产品线的领先企业。公司玻尿酸产品呈梯度化分布，种类丰富且已建立先发优势；国产首款面部埋植线产品处于市场推广期，未来将逐步贡献业绩增量；童颜针预计于今年底获批，作为国产首款合规产品市场竞争格局优良，预计将加速替代非合规市场份额；此外，与韩国Huons合作研发的肉毒毒素产品临床进展顺利。预计未来公司将形成玻尿酸+肉毒毒素+胶原蛋白+埋植线等注射类全产品线布局的平台型医美企业。盈利调整与投资建议我们维持盈利预测，预计公司2020-2022年归母净利润分别为4.01亿元、6.22亿元、9.16亿元，分别同比增长31.1%、55.4%、47.2%。维持“增持”评级。风险提示玻尿酸产品市场竞争加剧导致净利率下滑风险；疫情影响下游需求恢复不及预期；产品推广不及预期；产品研发及注册进度不及预期；税收优惠变化风险等。01000200030004000500060007000305.78335.79365.8395.81425.82455.83485.84191028200128200428200728人民币(元)成交金额(百万元)成交金额爱美客沪深3002020年10月27日医药健康研究中心爱美客(300896.SZ)增持（维持评级）公司点评证券研究报告公司点评-2-敬请参阅最后一页特别声明附录：三张报表预测摘要损益表（人民币百万元）资产负债表（人民币百万元）2017201820192020E2021E2022E2017201820192020E2021E2022E主营业务收入2223215587081,1111,674货币资金2142665063,7723,9594,304增长率44.3%73.7%27.0%56.9%50.7%应收款项61117202943主营业务成本-31-34-41-55-82-121存货181323243552%销售收入13.9%10.7%7.4%7.8%7.4%7.2%其他流动资产9719306344393毛利1922875176531,0291,553流动资产2472965654,1224,3674,791%销售收入86.1%89.3%92.6%92.2%92.6%92.8%%总资产62.4%63.9%75.9%93.1%90.6%88.9%营业税金及附加-4-6-4-5-7-10长期投资000152030%销售收入1.6%1.9%0.6%0.7%0.6%0.6%固定资产130140151275418553销售费用-42-62-77-103-211-318%总资产32.9%30.1%20.3%6.2%8.7%10.3%%销售收入18.8%19.4%13.8%14.5%19.0%19.0%无形资产9911121314管理费用-26-44-48-61-94-141非流动资产149167179305454600%销售收入11.6%13.8%8.6%8.6%8.5%8.4%%总资产37.6%36.1%24.1%6.9%9.4%11.1%研发费用-28-34-49-71-112-171资产总计3964647444,4264,8215,392%销售收入12.8%10.5%8.7%10.0%10.1%10.2%短期借款000000息税前利润（EBIT）92140339414604914应付款项302318314973%销售收入41.4%43.6%60.8%58.5%54.4%54.6%其他流动负债2222494773109财务费用122448086流动负债52456778122182%销售收入-0.3%-0.5%-0.3%-6.3%-7.2%-5.1%长期贷款600000资产减值损失211112其他长期负债111414161617公允价值变动收益000000负债68598194139199投资收益31771013普通股股东权益3253986594,3364,6945,215%税前利润3.0%0.5%2.0%1.5%1.4%1.3%其中：股本909090120120120营业利润941433504686971,014未分配利润821443846259831,504营业利润率42.1%44.6%62.8%66.1%62.7%60.6%少数股东权益364-3-12-22营业外收支001101负债股东权益合计3964647444,4264,8215,392税前利润941433514696971,015利润率42.1%44.6%62.9%66.2%62.7%60.6%比率分析所得税-17-27-53-75-108-1572017201820192020E2021E2022E所得税率18.1%18.9%15.1%16.0%15.5%15.5%每股指标净利润77116298394589857每股收益0.9131.3653.3953.3324.9717.218少数股东损益-5-7-8-7-9-10每股净资产3.6124.4277.32136.06939.05243.382归属于母公司的净利润82123306401597868每股经营现金净流0.8821.4823.4353.4415.3317.725净利率36.9%38.3%54.8%56.6%53.8%51.8%每股股利0.2200.5500.5001.3331.9882.887回报率现金流量表（人民币百万元）净资产收益率25.29%30.84%46.37%9.24%12.73%16.64%2017201820192020E2021E2022E总资产收益率20.73%26.50%41.08%9.05%12.39%16.09%净利润77118298394589857投入资本收益率22.57%27.94%43.33%8.02%10.90%14.86%少数股东损益-5-7-8-7-9-10增长率非现金支出0710274868主营业务收入增长率58.09%44.28%73.74%26.98%56.88%50.65%非经营收益-64-6-7-11-14EBIT增长率55.68%52.28%142.15%22.10%45.92%51.17%营运资金变动84701418净利润增长率53.99%49.47%148.68%31.10%49.16%45.21%经营活动现金净流79133309414641929总资产增长率26.30%16.95%60.40%495.24%8.91%11.84%资本开支-43-39-33-136-190-201资产管理能力投资2900-295-35-50应收账款周转天数7.97.77.89.08.58.5其他31771013存货周转天数198.9162.7161.0160.0163.0165.0投资活动现金净流-11-38-26-424-215-238应付账款周转天数306.0260.6124.6120.0115.0113.0股权募资61073,43600固定资产周转天数165.6157.398.6115.797.978.1债权募资3-60111偿债能力其他-22-50-51-160-239-347净负债/股东权益-63.61%-65.61%-76.30%-93.53%-91.18%-89.63%筹资活动现金净流-12-46-443,277-238-346EBIT利息保障倍数-132.0-81.6-198.8-9.4-7.6-10.7现金净流量56492403,266187345资产负债率17.18%12.70%10.88%2.12%2.87%3.69%来源：公司年报、国金证券研究所公司点评-3-敬请参阅最后一页特别声明市场中相关报告评级比率分析日期一周内一月内二月内三月内六月内买入00000增持00000中性00000减持00000评分0.000.000.000.000.00来源：朝阳永续市场中相关报告评级比率分析说明：市场中相关报告投资建议为“买入”得1分，为“增持”得2分，为“中性”得3分，为“减持”得4分，之后平均计算得出最终评分，作为市场平均投资建议的参考。最终评分与平均投资建议对照：1.00=买入；1.01~2.0=增持；2.01~3.0=中性3.01~4.0=减持历史推荐和目标定价(人民币)序号日期评级市价目标价12020-10-10增持358.00377.94～377.94来源：国金证券研究所投资评级的说明：买入：预期未来6－12个月内上涨幅度在15%以上；增持：预期未来6－12个月内上涨幅度在5%－15%；中性：预期未来6－12个月内变动幅度在-5%－5%；减持：预期未来6－12个月内下跌幅度在5%以上。0501001502008.489.149.8010.4611.1211.7812.44200928成交量人民币(元)历史推荐与股价公司点评-4-敬请参阅最后一页特别声明特别声明：国金证券股份有限公司经中国证券监督管理委员会批准，已具备证券投资咨询业务资格。本报告版权归“国金证券股份有限公司”（以下简称“国金证券”）所有，未经事先书面授权，任何机构和个人均不得以任何方式对本报告的任何部分制作任何形式的复制、转发、转载、引用、修改、仿制、刊发，或以任何侵犯本公司版权的其他方式使用。经过书面授权的引用、刊发，需注明出处为“国金证券股份有限公司”，且不得对本报告进行任何有悖原意的删节和修改。本报告的产生基于国金证券及其研究人员认为可信的公开资料或实地调研资料，但国金证券及其研究人员对这些信息的准确性和完整性不作任何保证，对由于该等问题产生的一切责任，国金证券不作出任何担保。且本报告中的资料、意见、预测均反映报告初次公开发布时的判断，在不作事先通知的情况下，可能会随时调整。本报告中的信息、意见等均仅供参考，不作为或被视为出售及购买证券或其他投资标的邀请或要约。客户应当考虑到国金证券存在可能影响本报告客观性的利益冲突，而不应视本报告为作出投资决策的唯一因素。证券研究报告是用于服务具备专业知识的投资者和投资顾问的专业产品，使用时必须经专业人士进行解读。国金证券建议获取报告人员应考虑本报告的任何意见或建议是否符合其特定状况，以及（若有必要）咨询独立投资顾问。报告本身、报告中的信息或所表达意见也不构成投资、法律、会计或税务的最终操作建议，国金证券不就报告中的内容对最终操作建议做出任何担保，在任何时候均不构成对任何人的个人推荐。在法律允许的情况下，国金证券的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供多种金融服务。本报告反映编写分析员的不同设想、见解及分析方法，故本报告所载观点可能与其他类似研究报告的观点及市场实际情况不一致，且收件人亦不会因为收到本报告而成为国金证券的客户。根据《证券期货投资者适当性管理办法》，本报告仅供国金证券股份有限公司客户中风险评级高于C3级(含C3级）的投资者使用；非国金证券C3级以上(含C3级）的投资者擅自使用国金证券研究报告进行投资，遭受任何损失，国金证券不承担相关法律责任。此报告仅限于中国大陆使用。上海北京深圳电话：021-60753903传真：021-61038200邮箱：researchsh@gjzq.com.cn邮编：201204地址：上海浦东新区芳甸路1088号紫竹国际大厦7楼电话：010-66216979传真：010-66216793邮箱：researchbj@gjzq.com.cn邮编：100053地址：中国北京西城区长椿街3号4层电话：0755-83831378传真：0755-83830558邮箱：researchsz@gjzq.com.cn邮编：518000地址：中国深圳福田区深南大道4001号时代金融中心7GH","data":[{"id":"1","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"2020Q1-Q3公司实现营收4.64亿元，同比增长17.4%","content_offset":["619","650"],"indicators":[{"indicator_name":"营业收入","indicator_value":["4.64亿元","634","640"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"2020Q1-Q3公司实现营收4.64亿元，同比增长17.4%","content_offset":["619","650"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["17.4%","645","650"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"归母净利润2.90亿元，同比增长31.8%","content_offset":["651","672"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.90亿元","656","662"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"归母净利润2.90亿元，同比增长31.8%","content_offset":["651","672"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["31.8%","667","672"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"扣非后归母净利润2.80亿元，同比增长29.9%","content_offset":["673","697"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["2.80亿元","681","687"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"扣非后归母净利润2.80亿元，同比增长29.9%","content_offset":["673","697"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["29.9%","692","697"],"indicator_element":{"时间":["20Q1-Q3","621","628"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"2020Q3公司实现营收2.23亿元，同比增长43.2%","content_offset":["699","727"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2.23亿元","711","717"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"2020Q3公司实现营收2.23亿元，同比增长43.2%","content_offset":["699","727"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["43.2%","722","727"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"归母净利润1.43亿元，同比增长56.0%","content_offset":["728","749"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1.43亿元","733","739"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"归母净利润1.43亿元，同比增长56.0%","content_offset":["728","749"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["56.0%","744","749"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"扣非后归母净利润1.39亿元，同比增长55.7%","content_offset":["750","774"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["1.39亿元","758","764"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"扣非后归母净利润1.39亿元，同比增长55.7%","content_offset":["750","774"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["55.7%","769","774"],"indicator_element":{"时间":["2020Q3","699","705"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"Q3毛利率93.0%（去年同期93.3%）维持较高水平","content_offset":["819","846"],"indicators":[{"indicator_name":"毛利率","indicator_value":["93.0%","824","829"],"indicator_element":{"时间":["Q3","819","821"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["93.3%","834","839"],"indicator_element":{"时间":["去年同期","830","834"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"因疫情线下营销活动减少，故销售费用率8.3%（去年同期10.6%）有所下滑","content_offset":["847","884"],"indicators":[{"indicator_name":"销售费用率","indicator_value":["8.3%","865","869"],"indicator_element":{"时间":["Q3","775","777"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销售费用率","indicator_value":["10.6%","874","879"],"indicator_element":{"时间":["去年同期","870","874"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"管理费用率5.1%（去年同期7.7%）","content_offset":["885","904"],"indicators":[{"indicator_name":"管理费用率","indicator_value":["5.1%","890","894"],"indicator_element":{"时间":["Q3","819","821"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"管理费用率","indicator_value":["7.7%","899","903"],"indicator_element":{"时间":["去年同期","895","899"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"研发费用率5.5%（去年同期6.7%）","content_offset":["905","924"],"indicators":[{"indicator_name":"研发费用率","indicator_value":["5.5%","910","914"],"indicator_element":{"时间":["Q3","819","821"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"研发费用率","indicator_value":["6.7%","919","923"],"indicator_element":{"时间":["去年同期","915","919"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"应收账款0.29亿元（年初0.15亿元）","content_offset":["925","945"],"indicators":[{"indicator_name":"收入","indicator_value":["0.29亿元","929","935"],"indicator_element":{"时间":["Q3","957","959"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["0.15亿元","938","944"],"indicator_element":{"时间":["年初","936","938"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"Q3经营性活动现金净流量1.43亿元（+48.5%）","content_offset":["957","983"],"indicators":[{"indicator_name":"经营性现金流","indicator_value":["1.43亿元","969","975"],"indicator_element":{"时间":["Q3","957","959"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"Q3经营性活动现金净流量1.43亿元（+48.5%）","content_offset":["957","983"],"indicators":[{"indicator_name":"经营性现金流同比","indicator_value":["48.5%","977","982"],"indicator_element":{"时间":["Q3","957","959"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"预计公司2020-2022年归母净利润分别为4.01亿元、6.22亿元、9.16亿元，分别同比增长31.1%、55.4%、47.2%","content_offset":["1389","1455"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["4.01亿元","1411","1417"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润","indicator_value":["6.22亿元","1418","1424"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润","indicator_value":["9.16亿元","1425","1431"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"21","source_document":"爱美客（300896）：Q3业绩加速增长，医美玻尿酸行业景气度高.pdf","content":"预计公司2020-2022年归母净利润分别为4.01亿元、6.22亿元、9.16亿元，分别同比增长31.1%、55.4%、47.2%","content_offset":["1389","1455"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["31.1%","1438","1443"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润同比","indicator_value":["55.4%","1444","1449"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润同比","indicator_value":["47.2%","1450","1455"],"indicator_element":{"时间":["2020-2022年","1393","1403"],"公司":["爱美客","1651","1654"]},"indicator_supplement":{"属性":"预计"}}]}]}